Allison Hagerman Acquires 10,000 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Allison Hagerman acquired 10,000 shares of Oncolytics Biotech stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average cost of C$1.14 per share, for a total transaction of C$11,400.00. Following the completion of the purchase, the insider directly owned 79,842 shares of the company’s stock, valued at C$91,019.88. This represents a 14.32% increase in their ownership of the stock.

Oncolytics Biotech Price Performance

The firm has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. Oncolytics Biotech Inc. has a fifty-two week low of C$0.44 and a fifty-two week high of C$2.08. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The stock has a 50-day moving average price of C$14.90 and a 200-day moving average price of C$13.02.

Oncolytics Biotech (TSE:ONC) last released its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. On average, equities research analysts expect that Oncolytics Biotech Inc. will post -0.41 EPS for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.